Address
Email address
Phone number
https://vitabalans.comVitabalans - suomalainen lääketehdas, oivallinen yritysKehitämme, valmistamme ja markkinoimme resepti- ja itsehoitolääkkeitä, ravintolisiä sekä eläinvalmisteita. Tunnetuimpia brändejämme apteekkisektorilla ovat mm. Ibumax, Paramax, Ampikyy, Arthrobalans, Biotiini Strong, Vita B12, Ferrodan, LactoSeven, Magnex ja Unital.
Name
Vitabalans Pharma OÜ
Registry code
11070110
VAT number
EE100926945
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
21.09.2004 (20)
Financial year
01.07-30.06
Capital
2 556.00 €
Activity
82991 - Other business support service activities n.e.c.
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Osaühing LEINONEN 10391964 | - | Contact person | - |
| 2019 09.10.2020 | 2020 08.10.2021 | 2021 27.10.2022 | 2022 29.12.2023 | |
|---|---|---|---|---|
| Total Revenue | 587 728 € | 639 974 € | 737 485 € | 845 770 € |
| Net profit (loss) for the period | 27 987 € | -29 525 € | 22 366 € | 28 375 € |
| Profit Margin | 5% | -5% | 3% | 3% |
| Current Assets | 488 058 € | 268 184 € | 182 470 € | 151 595 € |
| Fixed Assets | 21 931 € | 9 969 € | 15 965 € | 12 209 € |
| Total Assets | 509 989 € | 278 153 € | 198 435 € | 163 804 € |
| Current Liabilities | 73 563 € | 111 252 € | 94 750 € | 104 844 € |
| Non Current Liabilities | - | - | - | - |
| Total Liabilities | - | - | - | - |
| Share Capital | - | - | - | - |
| Equity | 436 426 € | 166 901 € | 103 685 € | 58 960 € |
| Employees | 3 | 3 | 3 | 2 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 243 709.6 € | 22 990.67 € | 19 293.5 € | 2 |
| 2023 Q4 | 260 565.58 € | 20 013.25 € | 17 396.85 € | 2 |
| 2023 Q3 | 235 165.95 € | 27 499.91 € | 27 115.71 € | 2 |
| 2023 Q2 | 198 740.03 € | 15 873.4 € | 14 789.54 € | 2 |
| 2023 Q1 | 210 921.15 € | 27 714.08 € | 13 950.12 € | 2 |
| 2022 Q4 | 205 455.43 € | 27 091.12 € | 27 068.31 € | 2 |
| 2022 Q3 | 207 060.79 € | 17 947.63 € | 16 994.27 € | 2 |
| 2022 Q2 | 221 693.83 € | 22 820.38 € | 22 859.33 € | 3 |
| 2022 Q1 | 152 171.15 € | 17 194.4 € | 15 690.92 € | 3 |
| 2021 Q4 | 175 375.86 € | 31 885.61 € | 15 918.48 € | 3 |
| 2021 Q3 | 205 109 € | 24 781.86 € | 25 704.05 € | 3 |
| 2021 Q2 | 150 007.76 € | 20 263.21 € | 21 204.21 € | 3 |
| 2021 Q1 | 147 943.64 € | 73 210.44 € | 12 599.64 € | 3 |
| 2020 Q4 | 162 980.73 € | 14 754.04 € | 14 924.75 € | 2 |
| 2020 Q3 | 150 162.1 € | 27 605.14 € | 29 314.27 € | 2 |
| 2020 Q2 | 149 666.32 € | 12 756.67 € | 13 282.7 € | 3 |
| 2020 Q1 | 138 103.63 € | 16 930.24 € | 16 299.37 € | 3 |
